Alnylam Pharmaceuticals said this week that it has appointed Robert Millman as chief patent counsel.
Millman, who has served as a consultant to Alnylam since June 2003, will be responsible for directing all aspects of the company’s intellectual property activities, said Alnylam.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
